Table 2 Treatments used adjunctively with DEX implant for complications of RVO in treatment-naïve patients
Treatments used in addition to DEX implant | Treatment-naïve patients |
|---|---|
(N = 39) | |
Any treatment, n (%) | 27 (69.2) |
Intravitreal injection | |
Anti-VEGF, n (%) | 23 (59.0) |
Ranibizumab, n (%) | 16 (41.0) |
Bevacizumab, n (%) | 9 (23.1) |
Mean number of ranibizumab or bevacizumab injections in patients receiving anti-VEGF | 3.2 |
Range | 1–6 |
Laser photocoagulation | |
Focal, n (%) | 11 (28.2) |
Panretinal, n (%) | 1 (2.6) |